Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 21, Issue 18, Pages 2293-2303Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2020.1806821
Keywords
Human respiratory syncytial virus; virus infection; prophylactic drugs; pharmacologic treatment
Categories
Funding
- FONDECYT [1190830]
- Millennium Institute on Immunology and Immunotherapy [P09/016-F]
- COPEC-UC [2019]
Ask authors/readers for more resources
Introduction Human respiratory syncytial virus (hRSV) is the primary viral cause of respiratory diseases, leading to bronchiolitis and pneumonia in vulnerable populations. The only current treatment against this virus is palliative, and no efficient and specific vaccine against this pathogen is available. Areas covered The authors describe the disease symptoms caused by hRSV, the economic and social impact of this infection worldwide, and how this infection can be modulated using pharmacological treatments, preventing and limiting its dissemination. The authors discuss the use of antibodies as prophylactic tools -such as palivizumab- and the use of nonspecific drugs to decrease the symptoms associated with the infection -such as bronchodilators, corticoids, and antivirals. They also discuss current vaccine candidates, new prophylactic treatments, and new antivirals options, which are currently being tested. Expert opinion Today, many researchers are focused on developing different strategies to modulate the symptoms induced by hRSV. However, to achieve this, understanding how current treatments are working and their shortcomings needs to be further elucidated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available